You are here

Pharmaceutical Approval Update December 2010

Marvin M. Goldenberg, PhD, RPh, MS
PDF version: 
Topics include onabotulinumtoxinA (Botox) for migraine; dabigatran (Pradaxa) for reducing stroke and embolism risk; and lurasidone (Latuda) for schizophrenia.